Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
RESEARCH TOOLSreports
Holding ETON?
Track your performance easily
ETON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.03 - $13.98
Previous Close$12.74
Volume125.78K
Average Volume (3M)222.67K
Market Cap
$336.66M
Enterprise Value$320.65M
Total Cash (Recent Filing)$20.26M
Total Debt (Recent Filing)$4.25M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Mar 13, 2025EPS Estimate
-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding25,836,204
10 Day Avg. Volume160,931
30 Day Avg. Volume222,673
Standard Deviation0.19
R-Squared0.15
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)20.39
Price to Sales (P/S)9.49
Price to Cash Flow (P/CF)27.00
P/FCF Ratio25.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.32
Enterprise Value/Gross Profit15.23
Enterprise Value/Ebitda-184.18
Forecast
1Y Price Target
$15.00Price Target Upside25.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Eton Pharmaceuticals News
PremiumCompany Announcements
Eton Pharmaceuticals Reports Strong Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEton reported $10.3M of revenues, beating consensus estimate of $9.7M.
Market PotentialAmglidia has the potential to fill a current gap in the U.S. market for neonatal diabetes mellitus oral treatment.
Product ExpansionThe acquisition of Amglidia is synergistic with the company’s existing pediatric endocrinology commercial portfolio and could contribute to long-term revenue growth for Eton.
Bears Say
Commercial RisksCommercial challenges could hinder the company's ability to maintain or grow its market share.
Dilution RisksPotential dilution could negatively impact shareholder value and investor confidence.
Legal And Intellectual Property ChallengesLegal and intellectual property challenges present significant risks to the stock's performance.
---
Ownership Overview
14.67% Insiders
7.27% Mutual Funds
26.63% Other Institutional Investors
47.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ETON FAQ
What was Eton Pharmaceuticals Inc’s price range in the past 12 months?
Eton Pharmaceuticals Inc lowest stock price was $3.03 and its highest was $13.98 in the past 12 months.
What is Eton Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Eton Pharmaceuticals Inc’s upcoming earnings report date?
Eton Pharmaceuticals Inc’s upcoming earnings report date is Mar 13, 2025 which is in 84 days.
How were Eton Pharmaceuticals Inc’s earnings last quarter?
Eton Pharmaceuticals Inc released its earnings results on Nov 12, 2024. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.03.
Is Eton Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued.
Does Eton Pharmaceuticals Inc pay dividends?
Eton Pharmaceuticals Inc does not currently pay dividends.
What is Eton Pharmaceuticals Inc’s EPS estimate?
Eton Pharmaceuticals Inc’s EPS estimate is -$0.01.
How many shares outstanding does Eton Pharmaceuticals Inc have?
Eton Pharmaceuticals Inc has 26,634,796 shares outstanding.
What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?
Eton Pharmaceuticals Inc reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 15.594%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ETON
---
Eton Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (25.94% Upside)
$15.00 (25.94% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $513.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
Fundamentals
Return on Equity
-33.35%
Trailing 12-Months
Asset Growth
13.69%
Trailing 12-Months
Company Description
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines. The company was founded in April 2017 and is headquartered in Deer Park, IL.
---
ETON Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, highlighting significant revenue growth, a strategic acquisition, and achieving profitability ahead of schedule. While there were challenges such as increased administrative expenses and higher discontinuation rates for a specific product, they were outweighed by the company's overall achievements and strategic advancements.Read More>---
ETON Stock 12 Month Forecast
Average Price Target
$15.00
▲(25.94% Upside)
Technical Analysis
Best Analysts Covering ETON
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+146.72%
assigned a buy rating 6 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +146.72% per trade.
---